Almudena Mateu-Puchades
Overview
Explore the profile of Almudena Mateu-Puchades including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cortell-Fuster C, Martinez-Gomez M, Cercos-Lleti A, Climente-Marti M, Diaz-Corpas T, Mateu-Puchades A, et al.
Farm Hosp
. 2025 Feb;
PMID: 39955214
Objective: Topical rapamycin is the pharmacological treatment of choice for facial angiofibromas in rare tuberous sclerosis disease. A new, more advanced, and complex formula was developed in our pharmacy service:...
2.
Rodriguez-Fernandez K, Zarzoso-Foj J, Saez-Bello M, Mateu-Puchades A, Martorell-Calatayud A, Merino-Sanjuan M, et al.
Pharmaceutics
. 2025 Jan;
16(12.
PMID: 39771555
Patient care and control of inflammatory disorders, such as psoriasis, can be improved by model-informed precision dosing (MIPD) techniques based on population pharmacokinetic/pharmacodynamic (PK/PD) models. Clinical dose selection decisions based...
3.
Rodriguez-Fernandez K, Zarzoso-Foj J, Saez-Bello M, Mateu-Puchades A, Martorell-Calatayud A, Merino-Sanjuan M, et al.
Pharmaceutics
. 2024 Oct;
16(10).
PMID: 39458624
Background/objectives: Implementing model-informed precision dosing (MIPD) strategies guided by population pharmacokinetic/pharmacodynamic (PK/PD) models could enhance the management of inflammatory diseases such as psoriasis. However, the extent of individual experimental data...
4.
Cortell-Fuster C, Martinez-Gomez M, Cercos-Lleti A, Climente-Marti M, Diaz-Corpas T, Mateu-Puchades A, et al.
Farm Hosp
. 2024 Jun;
PMID: 38851908
Aim: Topical rapamycin is the pharmacological treatment of choice for facial angiofibromas in rare tuberous sclerosis disease. A new, more advanced, and complex formula was developed in our pharmacy service:...
5.
Docampo-Simon A, Belinchon I, Sanchez-Pujol M, Berbegal L, Miralles J, Lucas A, et al.
Int J Dermatol
. 2024 Mar;
63(10):1392-1397.
PMID: 38433076
Background: Psoriasis (Ps) and atopic dermatitis (AD) are chronic systemic immune-mediated diseases that can coexist in an overlapping condition called psoriasis dermatitis (PD). PD patients have intermediate lesions with characteristics...
6.
Aguado Vazquez A, Estebanez Corrales A, Melgosa Ramos F, Mascaro Galy J, Fulgencio-Barbarin J, Bosch Amate X, et al.
Clin Exp Dermatol
. 2024 Mar;
49(9):1002-1006.
PMID: 38430106
Background: Bullous pemphigoid (BP) is the most common autoimmune blistering disease. Most patients are older and have associated multiple comorbidities. Topical and systemic corticosteroids are considered the first-line treatment for...
7.
Berenguer-Ruiz S, Aparicio-Dominguez M, Herranz-Pinto P, Ruiz-Villaverde R, Lopez-Ferrer A, Santos-Juanes J, et al.
J Eur Acad Dermatol Venereol
. 2023 Aug;
37(12):2517-2525.
PMID: 37625815
Background: Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate-to-severe plaque psoriasis. Real-world evidence on the...
8.
Palacios-Diaz R, Sahuquillo-Torralba A, Rocamora-Duran V, de Unamuno-Bustos B, Salavert-Lleti M, Santos-Alarcon S, et al.
J Dtsch Dermatol Ges
. 2023 May;
21(5):473-481.
PMID: 37183744
No abstract available.
9.
Palacios-Diaz R, Sahuquillo-Torralba A, Rocamora-Duran V, de Unamuno-Bustos B, Salavert-Lleti M, Santos-Alarcon S, et al.
J Dtsch Dermatol Ges
. 2023 Apr;
21(5):473-480.
PMID: 37042124
Background And Objectives: The increasing use of biologics in the treatment of inflammatory diseases has led to more cases of leishmaniasis in patients subjected to iatrogenic immunosuppression. The main objective...
10.
Rodriguez-Fernandez K, Mangas-Sanjuan V, Merino-Sanjuan M, Martorell-Calatayud A, Mateu-Puchades A, Climente-Marti M, et al.
Pharmaceutics
. 2022 Mar;
14(3).
PMID: 35336028
The treatment of psoriasis has been revolutionized by the emergence of biological therapies. Monoclonal antibodies (mAb) generally have complex pharmacokinetic (PK) properties with nonlinear distribution and elimination. In recent years,...